Data catalogue

The aim of this catalogue is to make it easier to find data published by the EMCDDA. Currently, the list only contains a fraction of all data published by the agency over the years but we are adding to it all the time as part of our commitment to open data. Note that the aim of this catalogue is not necessarily to provide the data itself (though it may do so in some cases) but mainly to allow you to find the data.

The catalogue incudes:

  • The Statistical Bulletin which is mainly based on data submitted to the agency by the Reitox network of national focal points for the main reporting countries (27 EU Member States plus Türkiye and Norway) on a yearly basis and which forms the basis for the EMCDDA's annual overview of the drug situation in Europe, as well as other key outputs. These data are generally at the national level. The topics covered by these data sets include general population surveys, drug-related deaths, drug-related infectious diseases, treatment demand, markets and seizures data, etc. Only the most recent Statistical Bulletins are currently included.
  • Data from ongoing collaborations with networks or partner organisations, These data sets are usually at the city-level and are considered complementary sources to the main reported data sets. Examples include data from SCORE (wastewater), TEDI (drug.checking), Euro-DEN (hospital emergencies), ESCAPE (syringe residues), etc.
  • Data from studies or specific projects. These data sets are usually once-off and may be the result of primary research or based on aggregation of other existing data sets, or some combination of both. These data in the past have not been published in 'raw format' but are often included in PDFs or only made available as graphics, etc. Data from non-reporting countries (e.g. countries in the EU neighbourhood) are often published in this format,
  • Data which has been manipulated, combined, or further processed for the purposes of analysis, data visualisation or similar. This is almost always done when included as part of a publication or output and usually referred to as the 'source data'.
  • Data about the EMCDDA or activities e.g. accounts, expenditure or other data about the agency.
Title Publication date Data series Keywords
Annex tables to the European Drug Report 2023 amphetamine, cannabis, cocaine, drug-related deaths, high risk opioid use, HIV, injecting drug use, MDMA/ecstasy, methamphetamine, needle and syringe provision, opioids, prevalence and patterns of drug use, seizures of drugs
Source data for Drug-induced deaths in Europe – the current situation in Europe (European Drug Report 2023) drug-checking, drug-related infectious diseases, health harms of drug use, heroin, injecting drug use, opioids, prevalence and patterns of drug use, #EDR23
Source data for Harm reduction – the current situation in Europe (European Drug Report 2023) drug consumption facility, drug-checking, naloxone, needle and syringe provision, OAT (opioid agonist treatment), prison, #EDR23
Source data for Heroin and other opioids – the current situation in Europe (European Drug Report 2023) drug markets, heroin, opioids, potency/purity, prevalence and patterns of drug use, price, seizures of drugs, #EDR23
Source data for Injecting drug use in Europe – the current situation in Europe (European Drug Report 2023) drug-checking, drug-related infectious diseases, health harms of drug use, heroin, injecting drug use, opioids, prevalence and patterns of drug use, #EDR23
Source data for MDMA – the current situation in Europe (European Drug Report 2023) drug markets, MDMA/ecstasy, potency/purity, prevalence and patterns of drug use, price, seizures of drugs, synthetic drugs, #EDR23
Source data for New psychoactive substances – the current situation in Europe (European Drug Report 2023) drug markets, fentanils, NPS, potency/purity, prevalence and patterns of drug use, price, seizures of drugs, synthetic cannabinoids, synthetic cathinones, synthetic drugs, #EDR23
Source data for Opioid agonist treatment – the current situation in Europe (European Drug Report 2023) heroin, heroin-assisted treatment, methadone, OAT (opioid agonist treatment), opioids, treatment of drug use, #EDR23
Source data for Other drugs – the current situation in Europe (European Drug Report 2023) drug markets, GHB, hallucinogenic mushrooms, ketamine, LSD, prevalence and patterns of drug use, price, seizures of drugs, synthetic drugs, #EDR23
Source data for Synthetic stimulants– the current situation in Europe (European Drug Report 2023) amphetamine, drug markets, methamphetamine, potency/purity, prevalence and patterns of drug use, price, seizures of drugs, synthetic drugs, treatment monitoring, wastewater analysis, #EDR23
Statistical Bulletin 2023 — drug use and prison DUP amphetamine, cannabis, cocaine, heroin, MDMA/ecstasy, methamphetamine, prevalence and patterns of drug use, prison
Prevalence of drug use in Europe, based on most recent general population surveys (2021 or most recent year) GPS alcohol, amphetamine, cannabis, cocaine, LSD, MDMA/ecstasy, methamphetamine, prevalence and patterns of drug use, tobacco, young people, #EDR23
Source data for European Web Survey on Drugs 2021: Emerging findings in Georgia European Web Survey on Drugs (EWSD) European Web Survey on Drugs (EWSD), prevalence and patterns of drug use
Source data for European Web Survey on Drugs 2021: Emerging findings in Lebanon European Web Survey on Drugs (EWSD) European Web Survey on Drugs (EWSD), prevalence and patterns of drug use
Source data for European Web Survey on Drugs 2021: Emerging findings in Ukraine European Web Survey on Drugs (EWSD) European Web Survey on Drugs (EWSD), prevalence and patterns of drug use
Statistical Bulletin 2022 — drug law offences DLO criminal justice system, drug law offences, drug markets, law
Statistical Bulletin 2022 — drug use and prison DUP amphetamine, cannabis, cocaine, heroin, MDMA/ecstasy, methamphetamine, prevalence and patterns of drug use, prison
Statistical Bulletin 2022 — drug-related infectious diseases DRID DRID (key indicator), drug-related infectious diseases, hepatitis C virus (HCV), HIV, key indicators
Statistical Bulletin 2022 — health and social responses HSR health and social responses, OAT (opioid agonist treatment), treatment provision
Statistical Bulletin 2022 – prevalence and patterns of drug use in the general population alcohol, amphetamine, cannabis, cocaine, Gender and drugs, general population surveys (GPS), key indicators, LSD, MDMA/ecstasy, prevalence and patterns of drug use, tobacco, young people
Statistical Bulletin 2022 — price, purity and potency PPP amphetamine, cannabis, cocaine, drug markets, heroin, LSD, MDMA/ecstasy, methamphetamine, potency/purity, price, supply of drugs, supply reduction
Statistical Bulletin 2022 — problem drug use PDU Gender and drugs, injecting drug use, key indicators, problem drug use
Statistical Bulletin 2022 — seizures of drugs SZR amphetamine, cannabis, cocaine, drug markets, LSD, MDMA/ecstasy, methamphetamine, seizures of drugs, supply of drugs, supply reduction, trafficking
Statistical Bulletin 2022 — treatment demand data TDI cannabis, cocaine, Gender and drugs, heroin, key indicators, methamphetamine, TDI (key indicator), treatment of drug use
Statistical Bulletin 2022— overdose deaths DRD DRD (key indicator), drug-related deaths, Gender and drugs, health harms of drug use, key indicators, overdose
Top